Ask AI
ProCE Banner Activity

An Expert’s Guide to ASH 2024: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight key studies being presented at the upcoming 2024 ASH Annual Meeting and Exposition. CCO’s Independent Conference Coverage will include timely summaries and practical implications of the latest research and developments in hematology to help you stay at the forefront of advances in cancer care.

Released: December 05, 2024

Share

Faculty

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Professor of Medicine
Harvard Medical School
Director, Center for Lymphoma
Mass General Brigham Cancer Ins
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Foresight Diagnostics, Genentech, Gilead, Interius, Lilly, Miltenyi, Novartis, Roche, Seagen; researcher: Bristol Myers Squibb, Celgene, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Catherine M. Broome, MD

Professor of Medicine
Director of Cellular Apheresis
Lombardi Cancer Center
MedStar Georgetown University
Washington, DC

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Sanofi; researcher: Alpine.

Jonathon B. Cohen, MD, MS

Professor, Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jonathon B. Cohen, MD, MS: consultant/advisor/speaker: ADCT, AstraZeneca, BeiGene, Loxo/Lilly; researcher: AstraZeneca, Bristol Myers Squibb/Celgene, Genentech, HutchMed, Loxo/Lilly, Novartis, Takeda.

Corey Cutler, MD, MPH

Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Corey Cutler, MD, MPH: consultant/advisor/speaker: CareDx, Cimeio, CSL Behring, Incyte, OrcaBio, Oxford Immune Algorithmics, Sanofi, Syndax; publicly traded stock/stock options: Cimeio, OrcaBio, Oxford Immune Algorithmics.

Courtney D. DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Courtney D. DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab, GSK, Molecular Partners, Ryvu, Schrödinger, Servier.

Rami Komrokji, MD

Senior Member, Vice Chair
Section Head – Leukemia and MDS
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, Florida

Rami Komrokji, MD: steering committee: Keros; advisor/speaker: Bristol Myers Squibb, DSI, Geron, Jazz, PharmaEssentia, Rigel, Servier, Sobi, Sumitomo.

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Sagar Lonial, MD, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; other financial or material support: TG Therapeutics.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, GlaxoSmithKline, Johnson & Johnson, Moderna, Pfizer, Regeneron, Sanofi.

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: Syndax.

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology, Clinical Trails Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Hematology, Department of Internal Medicine, Yale School of Medicine
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MHS: consultant/advisor/speaker/clinical trial committee: AbbVie, Akeso, Agios, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, FibroGen, Glycomimetics, Genentech, Gilead, Geron, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Seattle Genetics, Servier, Shattuck Labs, Syndax, Syros, Takeda, Treadwell, Taiho, Vincerx, Zentalis.